Quantitative liver MRI biomarkers: what the radiologist should know
-
Published:2024-06-12
Issue:1
Volume:11
Page:
-
ISSN:3004-8613
-
Container-title:Journal of Medical Imaging and Interventional Radiology
-
language:en
-
Short-container-title:J Med Imaging Intervent Radiol
Author:
Mazzola MariasoleORCID, Cannella RobertoORCID, Pilato GiuliaORCID, Blandino Antonino AndreaORCID, Milazzo Monica, Matteini FrancescoORCID, Vernuccio FedericaORCID, Brancatelli GiuseppeORCID
Abstract
AbstractQuantitative MRI biomarkers are increasingly requested in clinical practice in the management of patients with chronic liver diseases, to evaluate fibrosis, steatosis, iron overloard and liver function. The proton density fat fraction (PDFF) is a quantitative biomarker for the quantification of steatosis, being the current noninvasive reference standard for steatosis grading. R2* is a biomarker of iron concentration and is bundled with PDFF. MR elastography measures liver stiffness through the quantification of mechanical waves generated by an external drive and it can be used to detect significant and advanced fibrosis. Hepatobiliary phase can provide information on residual liver function by quantitative or semiquantitative parameters. The functional liver imaging score is an emerging semiquantitative tool based on the three hepatobiliary phase features: liver parenchymal enhancement, biliary contrast excretion, and portal vein sign. This work discusses the role of quantitative MRI biomarkers, offering practical tips for the diagnosis of steatosis, iron, fibrosis and liver function.
Publisher
Springer Science and Business Media LLC
Reference38 articles.
1. Moon AM, Singal AG, Tapper EB (2020) Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol 18(12):2650–2666. https://doi.org/10.1016/j.cgh.2019.07.060 2. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Narro GEC, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-Gómez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN, NAFLD Nomenclature consensus group (2024) A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol 29(1):101133. https://doi.org/10.1016/j.aohep.2023.101133 3. Yokoo T, Serai SD, Pirasteh A, Bashir MR, Hamilton G, Hernando D, Hu HH, Hetterich H, Kühn JP, Kukuk GM, Loomba R, Middleton MS, Obuchowski NA, Song JS, Tang A, Wu X, Reeder SB, Sirlin CB, RSNA-QIBA PDFF Biomarker Committee (2018) Linearity, bias, and precision of hepatic proton density fat fraction measurements by using MR imaging: a meta-analysis. Radiology 286(2):486–498. https://doi.org/10.1148/radiol.2017170550 4. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM (2011) Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 54(3):1082–1090. https://doi.org/10.1002/hep.24452 5. Ferraioli G, Soares Monteiro LB (2019) Ultrasound-based techniques for the diagnosis of liver steatosis. World J Gastroenterol 25(40):6053–6062. https://doi.org/10.3748/wjg.v25.i40.6053
|
|